THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY

被引：0
|
作者：
Hillmen, P. [1 ]
Rawstron, A. [2 ]
Munir, T. [3 ]
Brock, K. [4 ]
Vincente, S. Munoz [4 ]
Jefferson, Y. [4 ]
Paterson, K. [4 ]
Fox, C. P. [5 ]
Gribben, J. [6 ]
Bloor, A. [7 ]
Schuh, A. [8 ]
Forconi, F. [9 ]
机构：
[1] Univ Leeds, Expt Haematol, Leeds, W Yorkshire, England
[2] St Jamess Inst Oncol, HMDS, Leeds, W Yorkshire, England
[3] St Jamess Inst Oncol, Haematol, Leeds, W Yorkshire, England
[4] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
[5] NHS Nottingham Univ Hosp, Nottingham, England
[6] Barts Canc Inst, London, England
[7] Christie Hosp NHS Trust, Manchester, Lancs, England
[8] Oxford Univ Hosp, Churchill Hosp, Oxford, England
[9] Southampton Gen Hosp, Southampton, Hants, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S770
引用
收藏
页码：311 / 311
页数：1
相关论文
共 20 条
  • [1] The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy
    Munoz-Vicente, Samuel
    Bishop, Rebecca
    Hillmen, Peter
    Munir, Talha
    Rawstron, Andy
    Brock, Kristian
    Fox, Christopher
    Gribben, John
    Bloor, Adrian
    Jefferson, Yolande
    Schuh, Anna
    Forconi, Francesco
    LEUKEMIA & LYMPHOMA, 2017, 58 : 239 - 239
  • [2] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Munir, T.
    Rawstron, A.
    Brock, K.
    Vicente, S. Munoz
    Yates, F.
    Bishop, R.
    Macdonald, D.
    Fegan, C.
    McCaig, A.
    Schuh, A.
    Pettitt, A.
    Gribben, J. G.
    Patten, P. E.
    Devereux, S.
    Bloor, A.
    Fox, C. P.
    Forconi, F.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 25 - 25
  • [3] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Hillmen, Peter
    Rawstron, Andy
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Macdonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    BLOOD, 2018, 132
  • [4] Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    Munir, Talha
    Rawstron, Andrew
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca
    Bishop, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John
    Patten, Piers
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher
    Forconi, Francesco
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2020, 61 : 227 - 228
  • [5] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 20 - 21
  • [6] Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy
    Hillmen, Peter
    Munir, Talha
    Rawstron, Andy
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Fegan, Christopher
    Macdonald, Donald
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    BLOOD, 2017, 130
  • [7] Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy
    Munir, Talha
    Rawstron, Andrew
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Fegan, Christopher
    Macdonald, Donald
    Mccaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher
    Forconi, Francesco
    Hillmen, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 34 - 35
  • [8] Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Punnoose, Elizabeth A.
    Cordero, Jaclyn
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed Hamed
    Freise, Kevin J.
    Leverson, Joel D.
    Enschede, Sari Heitner
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Harrison, Simon J.
    BLOOD, 2017, 130 (22) : 2392 - 2400
  • [9] Continued Long Term Responses to Ibrutinib plus Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial
    Hillmen, Peter
    Boucher, Rebecca H.
    Webster, Nichola
    Dalal, Surita
    Brock, Kristian
    Yates, Francesca
    Sankhalpara, Chhaya
    Macdonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Rawstron, Andrew
    Hillmen, Peter
    BLOOD, 2020, 136
  • [10] Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
    Portell, Craig A.
    Chen, Robert W.
    Wages, Nolan
    Cohen, Jonathon B.
    Weber, Michael J.
    Petroni, Gina
    Kahl, Brad S.
    Williams, Michael E.
    BLOOD, 2016, 128 (22)
12